Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Apixaban	Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)	Specialist initiation for the treatment and secondary prevention of DVT and/or PE - use in line with NICE and supported by RICaD
Apixaban	Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (TA275)	Second choice following diagnosis of AF - use in line with NICE Anticoagulant Initiation Flowchart for Anticoagulation in Atrial Fibrillation
Apixaban	Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245)	Use following hip and knee surgery - full course of treatment supplied on discharge
Apremilast	TA419 - Apremilast for treating moderate to severe plaque psoriasis TA433 - Apremilast for treating active psoriatic arthritis
Aripiprazole tablets	TA213 - Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years TA292 - Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder	Supported by ESCA. The GP should be given a rationale for prescribing rather than first line antipsychotics. Approved for use in Tourette's Syndrome.
Arsenic trioxide	TA526 - Arsenic trioxide for treating acute promyelocytic leukaemia	Hospital use only
Asciminib	TA813: Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors
Atezolizumab (Tecentriq®)	TA739 - Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable TA823: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
Atezolizumab (Tecentriq®)	TA492 - Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable TA520 - Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy TA525 - Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy TA333 - Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment TA584 - Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer TA639 - Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer TA638 - Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer TA666 - Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma TA705 - Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer	Hospital use only
Avacopan (Tavneos®)	TA825: Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.